PROPANC BIOPHARMA, INC.: research and development expense
Research and development expense for PROPANC BIOPHARMA, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All PROPANC BIOPHARMA, INC. financial histories
What this measure means
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
Exact concept: us-gaap:ResearchAndDevelopmentExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-07-01 to 2025-06-30. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-07-01 | 2025-06-30 | 223,721 | USD | 2025-09-29 | 10-K · 0001493152-25-016069 |
| 2023-07-01 | 2024-06-30 | 248,102 | USD | 2025-09-29 | 10-K · 0001493152-25-016069 |
| 2022-07-01 | 2023-06-30 | 247,919 | USD | 2024-09-30 | 10-K · 0001493152-24-038815 |
| 2021-07-01 | 2022-06-30 | 256,052 | USD | 2023-09-28 | 10-K · 0001493152-23-034632 |
| 2020-07-01 | 2021-06-30 | 230,956 | USD | 2022-09-28 | 10-K · 0001493152-22-027033 |
| 2019-07-01 | 2020-06-30 | 179,987 | USD | 2021-09-28 | 10-K · 0001493152-21-023973 |
| 2018-07-01 | 2019-06-30 | 260,335 | USD | 2020-10-01 | 10-K · 0001493152-20-018726 |
| 2017-07-01 | 2018-06-30 | 1,825,728 | USD | 2019-10-15 | 10-K · 0001493152-19-015529 |
| 2016-07-01 | 2017-06-30 | 971,769 | USD | 2018-09-17 | 10-K · 0001493152-18-013392 |
| 2015-07-01 | 2016-06-30 | 1,446,948 | USD | 2017-09-28 | 10-K · 0001493152-17-011027 |
| 2014-07-01 | 2015-06-30 | 134,319 | USD | 2016-09-28 | 10-K · 0001144204-16-125808 |
| 2013-07-01 | 2014-06-30 | 8,168 | USD | 2015-09-30 | 10-K · 0001144204-15-057458 |
| 2012-07-01 | 2013-06-30 | 12,344 | USD | 2014-10-14 | 10-K · 0001144204-14-060984 |
| 2011-07-01 | 2012-06-30 | 5,279 | USD | 2013-10-15 | 10-K · 0001354488-13-005698 |
| 2010-07-01 | 2011-06-30 | 385,777 | USD | 2012-10-15 | 10-K · 0001354488-12-005291 |
Related financial histories
- PROPANC BIOPHARMA, INC.: total assets
- PROPANC BIOPHARMA, INC.: total liabilities
- PROPANC BIOPHARMA, INC.: stockholders equity
- PROPANC BIOPHARMA, INC.: cash and cash equivalents
- PROPANC BIOPHARMA, INC.: net income or loss
- PROPANC BIOPHARMA, INC.: operating cash flow
- PROPANC BIOPHARMA, INC.: capital expenditure payments
- PROPANC BIOPHARMA, INC.: financing cash flow
- PROPANC BIOPHARMA, INC.: investing cash flow
- PROPANC BIOPHARMA, INC.: retained earnings or deficit
- PROPANC BIOPHARMA, INC.: basic weighted-average shares
- PROPANC BIOPHARMA, INC.: diluted weighted-average shares
- PROPANC BIOPHARMA, INC.: basic earnings per share
- PROPANC BIOPHARMA, INC.: diluted earnings per share
- PROPANC BIOPHARMA, INC.: income tax expense or benefit
- PROPANC BIOPHARMA, INC.: net property, plant and equipment
- PROPANC BIOPHARMA, INC.: share-based compensation expense
- PROPANC BIOPHARMA, INC.: operating income or loss
- PROPANC BIOPHARMA, INC.: current assets
- PROPANC BIOPHARMA, INC.: interest expense
- PROPANC BIOPHARMA, INC.: current liabilities
- PROPANC BIOPHARMA, INC.: current accounts payable
- PROPANC BIOPHARMA, INC.: operating expenses
Inspect the source
- Entity
- PROPANC BIOPHARMA, INC. / CIK 0001517681
- Captured
- 2026-09-20T09:14:07.933Z
- SEC response SHA-256
4f6eac6bf72e7f988a9a94ea85589b445974414449c4b417540ed20477181487
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001517681.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))